Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer.

Katelyn T ByrneCourtney B BettsRosemarie MickShamilene SivagnanamDavid L Bajor Daniel A Laheru E Gabriela ChioreanMark H O'HaraShannon M LiudahlCraig NewcombCécile AlanioAna P FerreiraByung S ParkTakuya OhtaniAustin P HuffmanSara A VäyrynenAndressa Dias CostaJudith C KaiserAndreanne M LacroixColleen RedlingerMartin SternJonathan A NowakE John WherryMartin A CheeverBrian M WolpinEmma E FurthElizabeth D Thompson Lisa M Coussens Robert A Anders

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

This unparalleled examination of CD40 mAb therapeutic mechanisms in patients provides insights for design of subsequent clinical trials targeting CD40 in cancer.

Keyphrases

clinical trial
end stage renal disease
newly diagnosed
ejection fraction
nk cells
locally advanced
prognostic factors
rectal cancer
papillary thyroid
cancer therapy
patient reported
childhood cancer